Gastric cancer in the era of molecularly targeted agents: current drug development strategies
- 11 April 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 135 (7), 855-866
- https://doi.org/10.1007/s00432-009-0583-7
Abstract
Gastric cancer is the second most common cause of cancer death worldwide with approximately one million cases diagnosed annually. Despite considerable improvements in surgical techniques, innovations in clinical diagnostics and the development of new chemotherapy regimens, the clinical outcome for patients with advanced gastric cancer and cancer of the GEJ is generally poor with 5-year survival rates ranging between 5 and 15%. The understanding of cancer relevant events has resulted in new therapeutic strategies, particularly in developing of new molecular targeted agents. These agents have the ability to target a variety of cancer relevant receptors and downstream pathways including the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor receptor (VEGFR), the insulin-like growth factor receptor (IGFR), the c-Met pathway, cell-cycle pathways, and down-stream signalling pathways such as the Akt-PI3k-mTOR pathway. In the era of new molecularly targeted agents this review focuses on recent developments of targeting relevant pathways involved in gastric cancer and cancer of the GEJ.Keywords
This publication has 92 references indexed in Scilit:
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203Journal of Clinical Oncology, 2010
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancerBritish Journal of Cancer, 2009
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerBritish Journal of Cancer, 2008
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisThe Lancet Oncology, 2008
- A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBritish Journal of Cancer, 2007
- Inhibition of heat shock protein 90 impairs epidermal growth factor–mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivoMolecular Cancer Therapeutics, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancerInternational Journal of Cancer, 2005
- Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell linesCancer Letters, 2004